 Genprex Inc NASDAQ:GNPX FRA:2DE is gearing up to enroll patients in its Acclaim-1 clinical trial evaluating its lead drug candidate REQORSA in combination with AstraZeneca PLCs LON:AZN NASDAQ:AZN Tagrisso osimertinib for late-stage non-small cell lung cancer following a review from regulator the US Food and Drug Administration FDA. The latter has reviewed and confirmed that all comments have been addressed regarding the protocol for the trial, which is an open-label, multi-center Phase 12 study testing the drug combined with Tagrisso in those whose disease has progressed after treatment with Tagrisso. 